We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




A Compound in Beer May Prevent Prostate Cancer

By LabMedica International staff writers
Posted on 08 Jan 2010
New research is highly suggestive that xanthohumol, a compound in beer, may prevent prostate cancer. More...
Tests revealed that xanthohumol blocked a biologic pathway that allows prostate cancer to be triggered by the male hormone testosterone.

Xanthohumol is derived from hops and belongs to the group of flavonoids that are found in many plants, fruit, spices, and vegetables. Earlier studies have shown that xanthohumol blocks the action of estrogen by binding to its receptor, which may lead to prevention of breast cancer.

Because testosterone receptors act similarly to that of estrogen--by binding, then stimulating hormone-dependent effects, such as gene expression and cell growth--the researchers examined whether xanthohumol might not only block the effects of estrogen, but also of the male hormone androgen.

Dr. Clarissa Gerhauser, from the German Cancer Research Center (Heidelberg, Germany), and colleagues stimulated hormone-dependent prostate cancer cells with testosterone, which led to a massive secretion of prostate-specific antigen (PSA).

PSA is used for screening and early detection of prostate cancer in men. Cells were then treated with testosterone and xanthohumol and the effects were examined. "Xanthohumol prevented the receptor from translocating to the cell nucleus, thus inhibiting its potential to stimulate the secretion of PSA and other hormone-dependent effects,” Dr. Gerhauser said.

Molecular modeling results demonstrated that xanthohumol directly binds to the androgen receptor structure. The researchers suggest that this compound may have beneficial effects in animals--when they measured the antiandrogenic potential of xanthohumol in a rat model, they discovered that although xanthohumol was not able to prevent an increase in prostate weight after testosterone treatment, it could reduce testosterone-increased seminal vesicle weight.

"Although the prostate weights were not changed, xanthohumol still reduced the effects of hormone signaling, such as gene expression, measured in the prostate tissue,” concluded Dr. Gerhauser.

The findings were presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held in Houston, TX, USA, December 6-9, 2009.

Related Links:

German Cancer Research Center



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.